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Calcification processes in a human body can be physiological - e.g. bone formation -, 
or pathologycal. Pathologycal soft tissue calcification, also known as ectopic calcification, is 
due to inappropriate biomineralization, and usually calcium phosphate salts are involved in 
the abnormal mineral deposition. Little is known about the mechanisms regulating the 
calcification processes, several metabolic and environmental factors are contributing to the 
aberrant mineralization, however, some rare monogenic disorders gave insight into the 
pathophysiological mechanisms contributing to arterial calcification. 
In 2000 it was found that mutations in the ABCC6 gene are responsible for the development 
of pseudoxanthoma elasticum (PXE), and recently mutations in the ABCC6 gene were found 
to be the genetic background in some cases of Generalized Arterial Calcification of Infancy 
(GACI). Both diseases are characterized by soft tissue calcification symptoms. Furthermore, 
a missing allele of ABCC6 is a genetic risk factor in coronary arterial disease, CAD. Based 
on these data ABCC6 seems to be a newly identified player in soft tissue calcification 
processes. 
Since the first PXE-causing mutations were discovered in 2000, the number of identified 
disease-causing variants of ABCC6 has exceeded 350, and most of them are missense 
mutations caused by amino acid substitutions. 
Amino acid substitutions in large plasma membrane proteins, such as ABCC6, generally 
result in decreased enzymatic activity, major folding and stability deficiency, poor plasma 
membrane targeting or a combination of these. Therefore, studying the consequence(s) of 
disease-causing missense mutations can provide important insights into the relationship 
between protein structure and pathological function. 
To understand the biochemical and cellular effects caused by ABCC6 mutations that lead to 
arterial and other soft tissue calcification in humans can help to find the appropriate therapy 
for PXE and GACI patients and may also help to better understand the mechanism of arterial 
calcification. 
 
In 2007 a disease was described with similar symptoms to PXE, and therefore it was named 
PXE-like disorder with multiple coagulation factor deficiency. This recently characterized 
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disease is caused by mutations in the gene of gamma-glutamyl carboxylase (GGCX) 
enzyme, and the symptoms include soft tissue calcification, just like in the case of PXE. The 
carboxylase enzyme is a key component of a cycle, in which vitamin K is a cofactor 
(vitamin K cycle). These data raised a hypothesis that the abnormal calcification symptoms 
in the above-mentioned diseases may be related to disrupted vitamin K cycle, and that 





In my PhD research program I focused on the subcellular localization of the ABCC6 
protein, on the investigation of the molecular background of disease-causing ABCC6 
mutations, and on how disease-causing mutations, resulting in improper localization, could 
be corrected. We also wanted to test the potential role of ABCC6 in vitamin K transport. 
 
Our specific aims were: 
1. To reinvestigate the plasma membrane localization of the wild type ABCC6 transporter 
and to determine the subcellular localization of disease-causing ABCC6 mutants. We 
planned to perform several immunocytochemical and immunohistochemical experiments 
on MDCKII cell line, on primary hepatocytes and also on mouse and human liver tissue. 
2. Our aim was to determine the molecular consequences of disease-causing missense 
mutations and to identify mutants with preserved transport activity but improper 
subcellular localization (probably due to protein folding problems). These mutants are 
candidates for pharmacological treatment in order to rescue the mislocalized protein. We 
planned to perform pharmacological correction experiments of mislocalized ABCC6 
mutants in vitro and in vivo. 
3. To test whether correcting the localization of the mutants results in a functional 
transporter, we aimed to develop an in vivo model system, based on determination of 
soft tissue calcification, to functionally investigate the ABCC6 protein.  
4. As a role of ABCC6 in Vitamin K metabolism was suggested, we aimed to prove or 
disprove this hypothesis investigating the potential role of ABCC6 in the transport of 






Sf9 (Spodoptera frugiperda) cells were cultured on 27°C, in TNM-FH insect medium 
supplied with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. 
MDCKII cells were cultured in a humidified 37°C, 5% CO2 incubator, in DMEM culture 
medium with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. In the 
localization-correction experiments cells were cultured in the presence of 1 mM 4-PBA. 
Animals 
All mice were kept under routine laboratory conditions with 12 hours light-dark cycle with 
access ad libitum to water and standard chow. Mice were euthanized by cervical dislocation. 
This study was approved by the Directorate of food safety and animal health control, 
Government Office for Pest County (permission number: XIV-I-001/707/4/2012). 
C57BL/6J, C3H/HeNHsd and Abcc6-/- mouse strains were used. 
DNA constructs 
The construction of DNA plasmids was based on the standard molecular biological methods. 
The ten ivestigated disease-causing ABCC6 mutantions were inserted into the human 
ABCC6 cDNA using site-directed mutagenesis by inverse PCR. The cDNA of wt and 
mutant ABCC6 was cut from pBluescript SK vector  and was inserted into pAcUW21 
baculoviral transfer vector. For retroviral transfection, ABCC6 cDNA was cut from 
pAcUW21-L vector and was ligated into SpSldS retroviral vector. For sleeping beauty 
transposon-based transfection, ABCC6 cDNA was first cut from pAcUW21-L vector and 
was ligated into a SB-CMV-ΔSma vector. Then in the second step ABCC6 was cut from this 
vector and inserted into SB vector containing a puromycin-resistance gene. For the tail vein 
injection ABCC6 cDNA constructs were sub-cloned into the pLIVE vector. 
Expression of wt and mutant forms of ABCC6 in SF9 cells 
For transfection of Sf9 cells we used BaculoGold kit (BD Biosciences Pharmingen). We 
isolated individual virus clones from the supernatant containing the recombinant viruses 
using the end-point dilution method.  
Expression of wt and mutant forms of ABCC6 in MDCKII cells 
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a) Retroviral transfection: Phoenix-Ampho packaging cells were transfected with the 
recombinant retrovirus vectors containing wt or mutant ABCC6. The transfection was 
performed using calcium phosphate transfection kit, according to the manufacturer's 
protocol. Cell clones overexpressing ABCC6 were selected by end-point dilution method. 
b) Sleeping Beauty (SB) transposon-based transfection: For the transfection the SB plasmid 
containing a puromycin-resistance gene and the wt or mutant forms of ABCC6, and a 
transposase plasmid were used. The transfection solution contained 2 µg SB-ABCC6 
plasmid, 0,2 µg 100x transposase and 6 µl FuGene HD reagent in 100µl serum-free DMEM 
medium. 48 hours after transfection cells were trypsinized and further cultured in cell 
culture flasks. 96 hours after transfection 3 µg/ml puromycin was added to the culture 
medium to select for the transfected cells. 
Expression of wt and mutant forms of ABCC6 in mouse liver 
PLIVE plasmid DNA constructs containing the wt or mutant ABCC6 were delivered into the 
mice by hydrodynamic tail vein injection. The tail vein injections were performed with a 27-
gauge needle with a volume of 1.8 ml of DNA in physiological salt solution. Mice were 
injected with 70 µg of plasmid. 
For the localization-correction studies mice received 3 intraperitoneal injections of 4-PBA 
(100 mg/kg/day) prior to performing hydrodynamic tail vein injections. 
Agarose gel electrophoresis and immunoblot 
Membrane vesicles or whole cell samples were taken up in loading buffer then were 
sonicated. Proteins were separated in a 7.5% SDS-poliacrylamid gel, then proteins were 
transferred from the gel to a nitrocellulose membrane using an electroblotting apparatus. 
After incubation with the appropriate antibodies, blots were revealed by enhanced 
chemiluminescence. 
Immunocytochemistry 
Cells were first washed, fixed with 4% paraformaldehide and precooled methanol, then were 
incubated with blocking buffer for 1 hour at RT. After removal of the blocking buffer, 
samples were incubated with the appropriate primary antibodies for 2 hours at RT. After 
washing, cells were incubated with the secondary antibodies for 1 hour. Nuclei were stained 
with DAPI for 5 minutes. Samples were kept at 4°C until microscope analysis. 
Immunohistochemistry 
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8 µm-thick frozen sections from the appropriate tissues were prepared using a cryotome. 
Slices were fixed in methanol, then washed in DPBS. After incubation in blocking buffer for 
1 hour, the appropriate primary antibodies were added for 90 minutes, followed by the 
incubation with secondary antibodies for 1 hour. Nuclei were stained with DAPI for 5 
minutes. Samples were kept at 4°C until microscope analysis. 
Isolation, culturing and immunocytochemistry of mouse primary hepatocytes 
Liver cells were isolated following the method published by Bayliss et al, 1996. Cells were 
plated in collagen-precoated dishes. After attachment of cells, medium was changed and 
renewed every 24h in the absence of serum. Immunocytochemistry was carried out after 72 
hours of cell culturing. 
Confocal microscope imaging 
Microscope images of fixed samples were acquired using a Zeiss LSM 710 confocal laser 
scanning microscope. Zeiss Zen software was used to evaluate data.  
Cryoinjury of mouse heart and determination of calcium deposition 
Cryoinjury was performed on 3-month-old mice. After anaesthesis, aseptic surgery was 
performed by entering the abdomen through a midline incision. A pre-cooled metal rod was 
applied with slight pressure to the heart muscle through the diaphragm for 10 seconds. After 
completion of the procedure, a two-layer abdominal closure was performed. Mice were 
euthanized 4 days after cryoinjury by cervical dislocation. Heart was taken out, washed in 
PBS solution, and the necrotic area of the heart was dissected. The heart sections were 
minced and left in 250 µl 0.15N HCl for 48 hours. The calcium content of the heart sections 
was determined by Calcium (CPC) LiquiColor Test. 
Membrane preparation and measuring protein content 
Sf9 cells were harvested, washed, centrifuged, then were homogenized using Potter-
Elvehjem tissue grinders. Cell debris was centrifuged and supernatant was ultracentrifuged 
(32000 rpm, 1 hour, 4°C). The membrane pellet was suspended, homogenized and aliquots 
of the membrane vesicles were kept at -80°C until use. Protein concentration of the 
membrane vesicles was determined by Lowry protein assay. 
Transport activity assay using membrane vesicles 
Sf9 membrane vesicles overexpressing wt or mutant ABCC6 were incubated with [3H]LTC4 
(130 Ci/mmol, PerkinElmer) in the presence or absence of 4 mM MgATP on 37°C in a 
 6	  
transport buffer. The transport reaction was terminated by ice-cold stop solution and the 
vesicles were transferred onto a nitrocellulose filter. Radioactivity was determined by liquid 
scintillation counter.  
Ex vivo liver perfusion  
Mice were anaesthetized, and after laparatomy, the portal vein and the inferior vena cava 
were cannulated. The blood in the liver was flushed out through the portal vein (in) and 
inferior vena cava (out), and the perfusate consisting of 0.5 or 50 µM vitamin K3 in 0.3% 
BSA/PBS was infused into the liver at a constant flow rate of 3 ml/min. Three ml of 
perfusate was held in the liver after the inferior vena cava and the portal veins were ligated. 
Five minutes later, the efflux was collected via the inferior vena cava. 
Extraction of vitamin K forms 
For vitamin K3 detection samples were deproteinated by 5% trichloroacetic acid. After 
vigorous vortexing samples were centrifuged and the supernatants were transferred into dark 
glass vials and kept at −20 °C for HPLC-MS/MS analysis.  
For vitamin K1 and K2 extraction first ethanol was added for deproteination, then K1 and 
K2 were extracted with n-hexane. After one minute vortexing samples were centrifuged, the 
hexane-phase was separated, and dried under a stream of nitrogen. The extracted material 
was dissolved in isopropanol, and kept at −20°C until HPLC-MS/MS analysis in sealed 
glass vials. 
Measure vitamin K concentration by HPLC-MS/MS 
Mass spectrometric measurements were run on an AB Sciex 3200 QTrap tandem mass 
spectrometer. The components were ionized in positive electrospray ionization (ESI) 
conditions. Samples were separated prior to mass spectrometric analysis using a Perkin 





- We proved the basolateral plasma membrane localization of both the human ABCC6 and 
the mouse Abcc6 transporter in primary hepatocytes and in intact liver tissue.  
- We have established an in vitro model system to investigate the subcellular localization 
of ABCC6 variants, generating stable MDCKII cell lines overexpressing the wt or 
mutant forms of ABCC6 by sleeping beauty transposon-based transduction system. 
- We have set up an in vivo model system suitable to investigate the expression and 
subcellular localization of human ABCC6 protein in mouse liver.  
- We have determined the transport activity and subcellular localization of ten disease-
causing ABCC6 mutants in vitro and in vivo. 
- We could determine the molecular background of the disease phenotype in case of the 
ten investigated disease-causing ABCC6 mutants. 
- 4-phenyl-butyrate (4-PBA) treatment was applied as a potential pharmacological rescue 
method. In MDCKII cell lines six mislocalized mutants were found to reach correct 
plasma membrane localization after the treatment, and the localization of four of the 
mutants was also corrected in mouse liver in vivo. These results serve as basis for future 
human therapeutic treatments. 
- A functional in vivo method - based on determination of soft tissue calcification - was set 
up, which is suitable to investigate the functional activity of human wt and mutant 
ABCC6 variants expressed in mouse liver. 
- Effective methods were established to extract vitamin K1, K2, K3 and K3-GS forms, 
and a sensitive detection method was developed for all these vitamin K forms. 
- Utilizing the above techniques the potential role of ABCC6 in vitamin K metabolism 
was investigated, and we proved that ABCC6 does not play a role in the transport of 
vitamin K3-gluthation conjugate. 
- We have also proved that dietary supplementation of vitamin K1 or K2 could not 
prevent PXE-related calcification, however, ABCC6 might be involved in vitamin K 





Our results, demonstrating basolateral plasma membrane localization of ABCC6 
both in mouse and human hepatocytes, gives a solid perspective for understanding the 
physiological role of ABCC6. 
The in vitro and in vivo model systems we developed were suitable to investigate the 
subcellular localization of wt and mutant variants of ABCC6 transporter. We also 
investigated the effect of 4-PBA, an FDA-approved drug, on the subcellular localization of 
ABCC6 mutants. 
Using the in vitro transport activity assay and investigating the subcellular 
localization of the ABCC6 variants we could determine the molecular background leading to 
the development of the disease phenotype. 
An interesting observation of this study was that non-polarized cells, polarized cells 
and mouse hepatocytes did not give identical results when investigating the subcellular 
localization of the mutants. The in vivo system, when overexpression of ABCC6 variants 
were executed in intact mouse liver, is surely closer to the physiological conditions of the 
human ABCC6 hepatic transporter compared to cell lines. 
Our results have valuable information about the subcellular localization of disease-
causing ABCC6 mutants and about the potential correction of intracellularly localized 
mutants by 4-PBA treatment. Some of the – otherwise intracellularly localized - mutants 
were found with correct plasma membrane localization upon 4PBA treatment. This is an 
important finding, as those intracellularly expressed mutants which could be rescued by 4-
PBA leading to correct plasma membrane localization are ideal candidates for further 
studies and may serve as basis of potential human therapies for those PXE or GACI patients 
who carry such disease-causing ABCC6 mutations. 
We have also developed an in vivo method using Abcc6 KO mice to monitor the 
function of ABCC6. This in vivo system is based on the determination of calcium 
deposition, and is suitable to study the functional activity of the disease-causing ABCC6 
mutants and to test whether those mutants which were previously found to be “rescued” to 
the plasma membrane after 4-PBA treatment are also functionally active. Results obtained 
from this combined in vivo model will be important steps toward future human therapies. 
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In addition, our finding that expression of ABCC6 in the liver alone was sufficient to 
reduce calcification, indicates that most probably the liver is the target organ of a future 
gene therapy in case of ABCC6-dependent genetic diseases. 
 
 Based on clinical observations, a potential role of ABCC6 in the transport of vitamin 
K was suggested. We tested this hypothesis, investigating K3-GS transport in an ex vivo 
system, and studying the effect of dietary K1 and K2 on the calcification in wt and Abcc6-/- 
mice. 
Our results demonstrated that Abcc6 is not involved in the transport of K3-GS and 
that neither K1, nor K2 could prevent calcification in Abcc6-/- mice, therefore vitamin K1 
and K2 at the periphery is not the limiting factor in the pathological calcification processes 
in PXE patients. 
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